Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
National Institutes of Health (NIH) · NIH Institute/Center · PAR-28-022
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $1.4M total
- DeadlineFinal application due date.
- Sep 25, 2029
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- P50
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 10
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Standard NIH dates
- Open dateWhen applications open (or opened).
- Oct 14, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $1.4M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Required
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). Based on the proposed research, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). This is a re-issuance of PAR-23-284 . The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. The research supported through this program must be translational and be based on human biology research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must reach a translational human endpoint within the project period of the grant.
Data notes: administering NIH institute could not be identified from the opportunity number.